Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ellin Berman

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Clinical Advances in Hematology & Oncology : H&O|February 18, 2011
Omacetaxine: the FDA decisionEllin Berman
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2014
Where exactly does ponatinib fit in chronic myelogenous leukemia?Ellin Berman
Current Opinion in Hematology|January 18, 2012
Genetic mutations in chronic myelogenous leukemia: when to check and what to do?Ellin Berman
Blood|September 16, 2021
How I treat chronic-phase chronic myelogenous leukemiaEllin Berman
Journal of the National Comprehensive Cancer Network : JNCCN|May 23, 2018
Pregnancy in Patients With Chronic Myeloid LeukemiaEllin Berman
Current Hematologic Malignancy Reports|February 10, 2023
Family Planning and Pregnancy in Patients with Chronic Myeloid LeukemiaEllin Berman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2018
Reply to D.M. Ross et al and V. Florou et alEllin Berman, Brian J Druker, Richard Burwick
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2018
Chronic Myelogenous Leukemia: Pregnancy in the Era of Stopping Tyrosine Kinase Inhibitor TherapyEllin Berman, Brian J Druker, Richard Burwick
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2018
Reply to N. Cerveira et alEllin Berman, Brian J Druker, Richard Burwick
Haematologica|March 12, 2026
Management of chronic myeloid leukemia with tyrosine kinase inhibitors: adverse events, toxicities and therapy dosingVivian G Oehler, Ellin Berman, Ivan J Huang
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Clinical Advances in Hematology & Oncology : H&O|February 18, 2011
Omacetaxine: the FDA decisionEllin Berman
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2014
Where exactly does ponatinib fit in chronic myelogenous leukemia?Ellin Berman
Current Opinion in Hematology|January 18, 2012
Genetic mutations in chronic myelogenous leukemia: when to check and what to do?Ellin Berman
Blood|September 16, 2021
How I treat chronic-phase chronic myelogenous leukemiaEllin Berman
Journal of the National Comprehensive Cancer Network : JNCCN|May 23, 2018
Pregnancy in Patients With Chronic Myeloid LeukemiaEllin Berman
Current Hematologic Malignancy Reports|February 10, 2023
Family Planning and Pregnancy in Patients with Chronic Myeloid LeukemiaEllin Berman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2018
Reply to D.M. Ross et al and V. Florou et alEllin Berman, Brian J Druker, Richard Burwick
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2018
Chronic Myelogenous Leukemia: Pregnancy in the Era of Stopping Tyrosine Kinase Inhibitor TherapyEllin Berman, Brian J Druker, Richard Burwick
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2018
Reply to N. Cerveira et alEllin Berman, Brian J Druker, Richard Burwick
Haematologica|March 12, 2026
Management of chronic myeloid leukemia with tyrosine kinase inhibitors: adverse events, toxicities and therapy dosingVivian G Oehler, Ellin Berman, Ivan J Huang
Pageof 5